TY - JOUR
T1 - Diagnostic Value of a Protocolized In-Depth Evaluation of Pediatric Bone Marrow Failure
T2 - A Multi-Center Prospective Cohort Study
AU - Atmar, Khaled
AU - Ruivenkamp, Claudia A. L.
AU - Hooimeijer, Louise
AU - Nibbeling, Esther A. R.
AU - Eckhardt, Corien L.
AU - Huisman, Elise J.
AU - Lankester, Arjan C.
AU - Bartels, Marije
AU - Santen, Gijs W. E.
AU - Smiers, Frans J.
AU - van der Burg, Mirjam
AU - Mohseny, Alexander B.
N1 - Funding Information: The authors would like to thank Erik von Asmuth, PhD-candidate at the Willem-Alexander Children’s Hospital (LUMC), for interpretation of the statistical documentation. We also thank the members of the pediatric society for bone marrow failure as well as Prof. Marc Raaijmakers and Dr. Stijn Halkes, for fruitful discussion during preparations for this study. Publisher Copyright: Copyright © 2022 Atmar, Ruivenkamp, Hooimeijer, Nibbeling, Eckhardt, Huisman, Lankester, Bartels, Santen, Smiers, van der Burg and Mohseny.
PY - 2022/4/27
Y1 - 2022/4/27
N2 - Background: Severe multilineage cytopenia in childhood caused by bone marrow failure (BMF) often represents a serious condition requiring specific management. Patients are at risk for invasive infections and bleeding complications. Previous studies report low rates of identifiable causes of pediatric BMF, rendering most patients with a descriptive diagnosis such as aplastic anemia (AA). Methods: We conducted a multi-center prospective cohort study in which an extensive diagnostic approach for pediatric patients with suspected BMF was implemented. After exclusion of malignant and transient causes of BMF, patients entered thorough diagnostic evaluation including bone marrow analysis, whole exome sequencing (WES) including copy number variation (CNV) analysis and/or single nucleotide polymorphisms (SNP) array analysis. In addition, functional and immunological evaluation were performed. Here we report the outcomes of the first 50 patients (2017-2021) evaluated by this approach. Results: In 20 patients (40%) a causative diagnosis was made. In this group, 18 diagnoses were established by genetic analysis, including 14 mutations and 4 chromosomal deletions. The 2 remaining patients had short telomeres while no causative genetic defect was found. Of the remaining 30 patients (60%), 21 were diagnosed with severe aplastic anemia (SAA) based on peripheral multi-lineage cytopenia and hypoplastic bone marrow, and 9 were classified as unexplained cytopenia without bone marrow hypoplasia. In total 28 patients had undergone hematopoietic stem cell transplantation (HSCT) of which 22 patients with an unknown cause and 6 patients with an identified cause for BMF. Conclusion: We conclude that a standardized in-depth diagnostic protocol as presented here, can increase the frequency of identifiable causes within the heterogeneous group of pediatric BMF. We underline the importance of full genetic analysis complemented by functional tests of all patients as genetic causes are not limited to patients with typical (syndromal) clinical characteristics beyond cytopenia. In addition, it is of importance to apply genome wide genetic analysis, since defects in novel genes are frequently discovered in this group. Identification of a causal abnormality consequently has implications for the choice of treatment and in some cases prevention of invasive therapies.
AB - Background: Severe multilineage cytopenia in childhood caused by bone marrow failure (BMF) often represents a serious condition requiring specific management. Patients are at risk for invasive infections and bleeding complications. Previous studies report low rates of identifiable causes of pediatric BMF, rendering most patients with a descriptive diagnosis such as aplastic anemia (AA). Methods: We conducted a multi-center prospective cohort study in which an extensive diagnostic approach for pediatric patients with suspected BMF was implemented. After exclusion of malignant and transient causes of BMF, patients entered thorough diagnostic evaluation including bone marrow analysis, whole exome sequencing (WES) including copy number variation (CNV) analysis and/or single nucleotide polymorphisms (SNP) array analysis. In addition, functional and immunological evaluation were performed. Here we report the outcomes of the first 50 patients (2017-2021) evaluated by this approach. Results: In 20 patients (40%) a causative diagnosis was made. In this group, 18 diagnoses were established by genetic analysis, including 14 mutations and 4 chromosomal deletions. The 2 remaining patients had short telomeres while no causative genetic defect was found. Of the remaining 30 patients (60%), 21 were diagnosed with severe aplastic anemia (SAA) based on peripheral multi-lineage cytopenia and hypoplastic bone marrow, and 9 were classified as unexplained cytopenia without bone marrow hypoplasia. In total 28 patients had undergone hematopoietic stem cell transplantation (HSCT) of which 22 patients with an unknown cause and 6 patients with an identified cause for BMF. Conclusion: We conclude that a standardized in-depth diagnostic protocol as presented here, can increase the frequency of identifiable causes within the heterogeneous group of pediatric BMF. We underline the importance of full genetic analysis complemented by functional tests of all patients as genetic causes are not limited to patients with typical (syndromal) clinical characteristics beyond cytopenia. In addition, it is of importance to apply genome wide genetic analysis, since defects in novel genes are frequently discovered in this group. Identification of a causal abnormality consequently has implications for the choice of treatment and in some cases prevention of invasive therapies.
KW - AA
KW - BMF
KW - aplastic anemia
KW - bone marrow failure
KW - cytopenia
KW - diagnostics
KW - next-generation sequencing
UR - http://www.scopus.com/inward/record.url?scp=85130047638&partnerID=8YFLogxK
U2 - https://doi.org/10.3389/fimmu.2022.883826
DO - https://doi.org/10.3389/fimmu.2022.883826
M3 - Article
C2 - 35572556
SN - 1664-3224
VL - 13
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 883826
ER -